Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced
by various factors, namely genetics, immunological processes, and environmental triggers such
as infection, obesity, smoking, and drugs.
The provision of probiotic Lactobacillus plantarum IS-10506, an Indonesian original probiotic
strain, is expected to be an effective, safe, and affordable alternative for psoriasis
treatment for psoriasis patients in Indonesia.
This study aimed to evaluate changes in gut microbiota profile, cytokines IL-17, TNF-a,
IL-10, Foxp3, and disease severity of psoriasis vulgaris patients after supplementation with
Lactobacillus plantarum IS-10506. The results of this study are expected to be the basis for
the use of Lactobacillus plantarum IS-10506 in the therapy of psoriasis vulgaris which is
included in the Clinical Practice Guide in Indonesia, which will ultimately help improve the
quality of life of psoriasis patients.